Epigenetic Repression of MicroRNA-129-2 Leads to Overexpression of SOX4 Oncogene in Endometrial Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Nov 6

PMID 19887623

Citations 131

Authors

Yi-Wen Huang

Joseph C Liu

Daniel E Deatherage

Jingqin Luo

David G Mutch

Paul J Goodfellow

David S Miller

Tim H-M Huang

Affiliations

Soon will be listed here.

Abstract

Genetic amplification, mutation, and translocation are known to play a causal role in the upregulation of an oncogene in cancer cells. Here, we report an emerging role of microRNA, the epigenetic deregulation of which may also lead to this oncogenic activation. SOX4, an oncogene belonging to the SRY-related high mobility group box family, was found to be overexpressed (P < 0.005) in endometrial tumors (n = 74) compared with uninvolved controls (n = 20). This gene is computationally predicted to be the target of a microRNA, miR-129-2. When compared with the matched endometria, the expression of miR-129-2 was lost in 27 of 31 primary endometrial tumors that also showed a concomitant gain of SOX4 expression (P < 0.001). This inverse relationship is associated with hypermethylation of the miR-129-2 CpG island, which was observed in endometrial cancer cell lines (n = 6) and 68% of 117 endometrioid endometrial tumors analyzed. Reactivation of miR-129-2 in cancer cells by pharmacologic induction of histone acetylation and DNA demethylation resulted in decreased SOX4 expression. In addition, restoration of miR-129-2 by cell transfection led to decreased SOX4 expression and reduced proliferation of cancer cells. Further analysis found a significant correlation of hypermethylated miR-129-2 with microsatellite instability and MLH1 methylation status (P < 0.001) and poor overall survival (P < 0.039) in patients. Therefore, these results imply that the aberrant expression of SOX4 is, in part, caused by epigenetic repression of miR-129-2 in endometrial cancer. Unlike the notion that promoter hypomethylation may upregulate an oncogene, we present a new paradigm in which hypermethylation-mediated silencing of a microRNA derepresses its oncogenic target in cancer cells.

Citing Articles

MicroRNA-129-3p Suppresses Tumor Progression and Chemoradioresistance in Head and Neck Squamous Cell Carcinoma.

Yoon T, Kim S, Jung E, Kim Y, Lee K, Lim S Curr Oncol. 2025; 32(1).

PMID: 39851970 PMC: 11763343. DOI: 10.3390/curroncol32010054.

Long Non-coding RNA FOXD2-AS1 Silencing Inhibits Malignant Behaviors of Ovarian Cancer Cells Via miR-324-3p/SOX4 Signaling Axis.

Xiang Y, Cheng X, Li H, Xu W, Zhang W Reprod Sci. 2024; .

PMID: 39455487 DOI: 10.1007/s43032-024-01719-0.

Crosstalk between miRNAs and DNA Methylation in Cancer.

Saviana M, Le P, Micalo L, Del Valle-Morales D, Romano G, Acunzo M Genes (Basel). 2023; 14(5).

PMID: 37239435 PMC: 10217889. DOI: 10.3390/genes14051075.

lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells.

Chen S, Liang Y, Shen Y, Wang X Exp Ther Med. 2023; 25(4):159.

PMID: 36911384 PMC: 9996364. DOI: 10.3892/etm.2023.11858.

MiR-133b regulates the proliferation, colony formation, and invasion of bladder cancer cells via inhibiting SOX4.

Zhong M, Jiang F, Song L, Nie M, Lan G Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(4):407-415.

PMID: 35545336 PMC: 10930165. DOI: 10.11817/j.issn.1672-7347.2022.210702.

References

Heidenblad M, Lindgren D, Jonson T, Liedberg F, Veerla S, Chebil G . Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics. 2008; 1:3. PMC: 2227947. DOI: 10.1186/1755-8794-1-3. View

Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J . Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008; 68(7):2094-105. DOI: 10.1158/0008-5472.CAN-07-5194. View

Pramoonjago P, Baras A, Moskaluk C . Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene. 2006; 25(41):5626-39. DOI: 10.1038/sj.onc.1209566. View

Zighelboim I, Goodfellow P, Gao F, Gibb R, Powell M, Rader J . Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol. 2007; 25(15):2042-8. DOI: 10.1200/JCO.2006.08.2107. View

Sinner D, Kordich J, Spence J, Opoka R, Rankin S, Lin S . Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007; 27(22):7802-15. PMC: 2169141. DOI: 10.1128/MCB.02179-06. View

Jones P, Baylin S . The epigenomics of cancer. Cell. 2007; 128(4):683-92. PMC: 3894624. DOI: 10.1016/j.cell.2007.01.029. View

Chen C, Ridzon D, Broomer A, Zhou Z, Lee D, Nguyen J . Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005; 33(20):e179. PMC: 1292995. DOI: 10.1093/nar/gni178. View

Liao Y, Sun Y, Chau G, Chau Y, Lai T, Wang J . Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene. 2008; 27(42):5578-89. DOI: 10.1038/onc.2008.168. View

Liu P, Ramachandran S, Seyed M, Scharer C, Laycock N, Dalton W . Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 2006; 66(8):4011-9. DOI: 10.1158/0008-5472.CAN-05-3055. View

10.

Lewis B, Shih I, Jones-Rhoades M, Bartel D, Burge C . Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-98. DOI: 10.1016/s0092-8674(03)01018-3. View

11.

Tavazoie S, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos P . Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451(7175):147-52. PMC: 2782491. DOI: 10.1038/nature06487. View

12.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

13.

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

14.

Scharer C, McCabe C, Ali-Seyed M, Berger M, Bulyk M, Moreno C . Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 2009; 69(2):709-17. PMC: 2629396. DOI: 10.1158/0008-5472.CAN-08-3415. View

15.

Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F . Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004; 64(9):3103-11. DOI: 10.1158/0008-5472.can-03-3968. View

16.

Hurst C, Fiegler H, Carr P, Williams S, Carter N, Knowles M . High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004; 23(12):2250-63. DOI: 10.1038/sj.onc.1207260. View

17.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

18.

Baylin S, Ohm J . Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006; 6(2):107-16. DOI: 10.1038/nrc1799. View

19.

Medina P, Castillo S, Blanco S, Sanz-Garcia M, Largo C, Alvarez S . The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet. 2009; 18(7):1343-52. DOI: 10.1093/hmg/ddp034. View

20.

Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen F, Thykjaer T, Sauter G . SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 2006; 66(7):3434-42. DOI: 10.1158/0008-5472.CAN-05-3456. View